- Home
- HRZN vs NGNE Comparison
HRZN vs NGNE Comparison
Compare HRZN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRZN
- NGNE
- Stock Information
- Founded
- HRZN 2008
- NGNE 2003
- Country
- HRZN United States
- NGNE United States
- Employees
- HRZN N/A
- NGNE N/A
- Industry
- HRZN Finance/Investors Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- HRZN Finance
- NGNE Health Care
- Exchange
- HRZN Nasdaq
- NGNE Nasdaq
- Market Cap
- HRZN 295.3M
- NGNE 325.3M
- IPO Year
- HRZN 2010
- NGNE N/A
- Fundamental
- Price
- HRZN $6.90
- NGNE $18.48
- Analyst Decision
- HRZN Hold
- NGNE Strong Buy
- Analyst Count
- HRZN 4
- NGNE 7
- Target Price
- HRZN $7.81
- NGNE $41.86
- AVG Volume (30 Days)
- HRZN 684.1K
- NGNE 110.1K
- Earning Date
- HRZN 08-07-2025
- NGNE 08-11-2025
- Dividend Yield
- HRZN 19.13%
- NGNE N/A
- EPS Growth
- HRZN N/A
- NGNE N/A
- EPS
- HRZN N/A
- NGNE N/A
- Revenue
- HRZN $97,144,000.00
- NGNE N/A
- Revenue This Year
- HRZN $0.51
- NGNE N/A
- Revenue Next Year
- HRZN $9.90
- NGNE N/A
- P/E Ratio
- HRZN N/A
- NGNE N/A
- Revenue Growth
- HRZN N/A
- NGNE N/A
- 52 Week Low
- HRZN $6.77
- NGNE $6.88
- 52 Week High
- HRZN $11.15
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- HRZN 30.61
- NGNE 35.93
- Support Level
- HRZN $6.86
- NGNE $19.59
- Resistance Level
- HRZN $6.96
- NGNE $20.46
- Average True Range (ATR)
- HRZN 0.09
- NGNE 1.23
- MACD
- HRZN -0.00
- NGNE -0.20
- Stochastic Oscillator
- HRZN 15.00
- NGNE 13.37
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.